Osteoporosis Care After Hip Fracture: A Regional Healthcare System Experience
Abstract Background: Pharmacologic treatment is recommended to reduce risk of future fractures and possibly reduce mortality in patients with hip fracture. We investigated osteoporosis care after hip fracture at a regional comprehensive healthcare system to identify rates of pharmacologic treatment after hip fracture and barriers to treatment. Methods: We identified all patients admitted with a low impact hip fracture between 1/2017-12/2018. Follow-up clinical data was collected for a minimum of 16 months after hip fracture. Results: 208 patients were admitted with low impact hip fractures: 130 (62%) were female, mean age was 79.6 (SD 12.6), 24 (12%) were nursing home resident, and 117 (56%) had BMI <25 kg/m2. At the time of the fracture, 80% had polypharmacy, 42% used mobility aide, 24% had known osteoporosis, 22% had dementia/cognitive impairment, 20% has history of cancer, 20% had history of stroke, 19% had diabetes and 2% were on dialysis. Two hundred (96%) underwent surgery. Forty-three (20%) had vitamin D level checked, of this, 20 (46%) had level <30 ng/mL. Prior to admission prescription of vitamin D was 53% and calcium was 36%. Discharge prescription of vitamin D was 64% and calcium was 50%. Prior to fracture, 18/208 (9%) were prescribed osteoporosis medication and at 1 year following fracture, 26/192 (14%) were prescribed osteoporosis medication (11 new, 15 continuation of medication). For follow up, 114/192 (59%) were seen in orthopedics clinic, 61 (32%) in primary care clinic, 2 (1%) in endocrinology clinic and 99 (52%) in other clinics. Sixteen (8%) patients died during the hospitalization for hip fracture and 47 (22%) died within 1 year. Conclusions: Osteoporosis treatment after hip fracture is suboptimal and a model of care is needed to close this care gap.